arrow
P

Pellegrino Musto

aouc policlinico
H指数:82
被引数:2.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy

多发性骨髓瘤患者在来那度胺维持治疗后进展的挽救治疗模式:欧洲骨髓瘤网络(EMN)意大利的真实世界研究

2026-09-050
OAAI
Effects of immunosuppressive and biological drugs in patients with asymptomatic monoclonal gammopathies (MGUS or smoldering myeloma) and concomitant autoimmune disorders: Results from the real-life MUSA study

免疫抑制药物和生物制剂在无症状单克隆丙种球蛋白病(MGUS或冒烟型骨髓瘤)伴发自身免疫性疾病患者中的效果:真实世界MUSA研究的结果

2026-08-210
PRE
The Dysregulation of the Integrated Stress Response in Leukemic Stem Cells as a Marker of Treatment Sensitivity in Acute Myeloid Leukemia

白血病干细胞中整合应激反应的失调作为急性髓系白血病治疗敏感性的标志物

Genes
IF2.8
2026-08-150
OAAI
Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients

EMN12/HOVON-129研究移植适宜队列中初发浆细胞白血病患者长期随访

2026-06-240
OAAI
Normal life expectancy after all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia

全反式维A酸和三氧化二砷治疗急性早幼粒细胞白血病后的正常预期寿命

Leukemia
IF13.4
2026-06-080
OAAI
One Grammar, Many Labels: Revisiting the Continuum of Myeloid Neoplasms

一种语法,多种标签:重新审视髓系肿瘤的连续统

2026-05-190
OA
Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström Macroglobulinaemia? A real-life multicentre Italian study.

伊布替尼或非BTK抑制剂疗法在复发华氏巨球蛋白血症中的应用?一项意大利多中心真实世界研究。

2026-02-160
OAAI
Outcome of Adult Lymphoblastic Lymphoma Patients Treated in the Real Life According to the Gimema LAL1913 Protocol: A Campus ALL Multicenter Study
2025-11-120
PRE
Correction: RUNX1A isoform is overexpressed in acute myeloid leukemia and is associated with FLT3 internal tandem duplications

更正:RUNX1A异构体在急性髓系白血病中过度表达,并与FLT3内部串联重复突变相关。

2025-11-030
OAAI
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework

支持意大利多发性骨髓瘤患者在DRd治疗后进行治疗的决策制定:一个多准则决策框架

2025-11-020
OAAI
Splenomegaly in de novo acute myeloid leukemia is associated with ASXL1 mutations together with a distinct clinical and gene expression profile

新诊断急性髓系白血病中的脾肿大与ASXL1突变相关,并伴有独特的临床和基因表达谱。

2025-10-230
OAAI
Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica Pugliese

单次与多次自体干细胞移植以及来那度胺维持治疗与无维持治疗在 newly-diagnosed 多发性骨髓瘤患者中的比较:来自 Rete Ematologica Pugliese 的真实世界数据,回顾二十三年来的研究进展

2025-10-100
OA
Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study

莫美洛替尼在骨髓纤维化患者中的疗效:一项多中心研究的结果

2025-09-010
OAAI
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience

Gilteritinib在FLT3突变急性髓系白血病中的治疗:一项意大利真实世界经验

Cancer
IF5.1
2025-08-210
OAAI
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168

更正:Mancuso等人,《Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma》,《Cancers》2025年第17卷第1168页。

2025-08-200
PRE
RUNX1A isoform is overexpressed in acute myeloid leukemia and is associated with FLT3 internal tandem duplications

RUNX1A异构体在急性髓系白血病中过表达,并与FLT3内部串联重复相关。

2025-07-150
OA